In the wise words of comedian Sarah Silverman, “Death creeps in through the gums.” While it may not be quite that clear-cut, the complications of periodontal disease—better known as gum disease—are far from pleasant.

CAR-T therapies targeting CD19 might be considered a hot ticket in biotech, but that hasn’t stopped French pharmaceutical research company Servier from scrapping its collaboration with Allogene Therapeutics.

New Jersey-based CRO Cognizant has seen its digital software program aimed at streamlining clinical trials and speeding up drug discoveries break the 250,000 user mark.

While many minor or moderate spinal cord injuries, or SCIs, can be at least partially healed with physical therapy, there are no treatments for the most severe cases. The problem lies in reconnecting axon fibers—the sections of nerve cells that carry signals from the brain along the spinal cord—below and above the injury site. Axon fibers have no natural regenerative response, and the parts of the cells that would normally promote growth, called the growth cones, collapse if the fiber is damaged.

Diabeloop has developed an artificial intelligence algorithm that, true to the French startup’s name, promises to close the diabetes management loop by connecting insulin pumps and continuous glucose monitors and completely automating the entire insulin delivery process.

Medtronic secured an FDA approval for the use of a new technique in placing its drug-eluting stents, to help treat the build-up of plaques that may clog the junction between two arteries feeding the heart.

A month after Acerus Pharmaceuticals announced the resignation of its chief financial officer, the company says it’s undergoing a strategic review to stay afloat.

Over the course of the last decade or so, smartphones have slowly morphed into full-fledged medical tools. Mobile devices are now being used to read diagnostic test results, scan photos taken by their built-in cameras to spot signs of disease and even to take the place of pulse oximeters in measuring blood oxygen levels.

Puma Biotechnology has gone looking for gems in Takeda’s castoffs, emerging from its rummaging with an aurora kinase A inhibitor that failed a phase 3 trial in 2015 but has since moved the needle in another study. The biotech landed a global license for $7 million upfront plus up to $287.3 million in milestones.

The latest study results for the BackBeat cardiac neuromodulation therapy device are music to Orchestra BioMed’s ears.